Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRSS1 | P07477 | 1/20 | 0.59 |
| ▸ | ACR | P10323 | 1/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 9/20 | 0.53 |
| ▸ | ATM | Q13315 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | GBA1 | P04062 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16604317 | 1.00 | PRSS1 (0.59) | PRSS1ACRCYP1A2SMN1; SMN2KMT2A | |
| SCHEMBL11105159 | 0.95 | PRSS1 (0.55) | PRSS1ACRCYP1A2SMN1; SMN2KMT2A | |
| SCHEMBL11102374 | 0.95 | PRSS1 (0.55) | PRSS1ACRCYP1A2SMN1; SMN2KMT2A | |
| SCHEMBL29009176 | 0.90 | KMT2A (0.61) | PRSS1CYP1A2SMN1; SMN2KMT2AATM | |
| SCHEMBL2838573 | 0.90 | KMT2A (0.61) | PRSS1CYP1A2SMN1; SMN2KMT2AATM | |
| SCHEMBL8929987 | 0.90 | PRSS1 (0.69) | PRSS1ACRCYP1A2SMN1; SMN2KMT2A | |
| SCHEMBL2741098 | 0.90 | PRSS1 (0.69) | PRSS1ACRCYP1A2SMN1; SMN2KMT2A | |
| SCHEMBL9663961 | 0.90 | PRSS1 (0.69) | PRSS1ACRCYP1A2SMN1; SMN2KMT2A | |
| SCHEMBL1101878 | 0.90 | PRSS1 (0.69) | PRSS1ACRCYP1A2SMN1; SMN2KMT2A | |
| SCHEMBL8930157 | 0.90 | PRSS1 (0.69) | PRSS1ACRCYP1A2SMN1; SMN2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1511713-B8 | COMPOUNDS THAT ABROGATE DNA-DAMAGE-INDUCED CELL CYCLE G2 CHECKPOINT AND/OR AUGMENT THE ANTI-CANCER ACTIVITY OF DNA-DAMAGING TREATMENTS | CANBAS CO LTD (JP) | 2012-02-08 | — | — | EP | claimed |
| EP-1511713-B1 | COMPOUNDS THAT ABROGATE DNA-DAMAGE-INDUCED CELL CYCLE G2 CHECKPOINT AND/OR AUGMENT THE ANTI-CANCER ACTIVITY OF DNA-DAMAGING TREATMENTS | CANBAS CO LTD (JP) | 2011-08-17 | — | — | EP | claimed |
| US-7652042-B2 | Compounds that abrogate DNA damage induced cell cycle G2 checkpoint and/or augment anti-cancer activity of DNA-damaging treatments | CANBAS CO., LTD. (JP) | 2010-01-26 | — | — | US | claimed |
| US-7629364-B2 | Compounds that abrogate DNA-damage-induced cell cycle G2 checkpoint and/or augment anti-cancer activity of DNA-damaging treatments | CANBAS CO., LTD. (JP) | 2009-12-08 | — | — | US | claimed |
| US-20080293137-A1 | COMPOUNDS THAT ABROGATE DNA DAMAGE INDUCED CELL CYCLE G2 CHECKPOINT AND/OR AUGMENT ANTI-CANCER ACTIVITY OF DNA-DAMAGING TREATMENTS | CANBAS CO., LTD. (JP) | 2008-11-27 | — | — | US | claimed |
| US-20080227827-A1 | COMPOUNDS THAT ABROGATE DNA DAMAGE INDUCED CELL CYCLE G2 CHECKPOINT AND/OR AUGMENT ANTI-CANCER ACTIVITY OF DNA-DAMAGING TREATMENTS | CANBAS CO., LTD. (JP) | 2008-09-18 | — | — | US | claimed |
| US-7407985-B2 | Compounds that abrogate DNA damage induced cell cycle G2 checkpoint and/or augment anti-cancer activity of DNA-damaging treatments | CANBAS CO., LTD. (JP) | 2008-08-05 | — | — | US | claimed |
| US-20060122269-A1 | Compounds that abrogate DNA damage induced cell cycle G2 checkpoint and/or augment anti-cancer activity of DNA-damaging treatments | CANBAS CO., LTD. (JP) | 2006-06-08 | — | — | US | claimed |
| US-7030111-B2 | Compounds that abrogate DNA-damage-induced cell cycle G2 checkpoint and/or augment the anti-cancer activity of DNA damaging treatments | CANBAS CO., LTD. (JP) | 2006-04-18 | — | — | US | claimed |
| US-20060014157-A1 | Sensitivity test to predict efficacy of anti-cancer therapies | CANBAS CO., LTD. (JP) | 2006-01-19 | — | — | US | claimed |
| EP-1511713-A2 | COMPOUNDS THAT ABROGATE DNA-DAMAGE-INDUCED CELL CYCLE G2 CHECKPOINT AND/OR AUGMENT THE ANTI-CANCER ACTIVITY OF DNA-DAMAGING TREATMENTS | Canbas Co. Ltd. (JP) | 2005-03-09 | — | — | EP | claimed |
| US-20040198727-A1 | Compounds that abrogate DNA-damage-induced cell cycle G2 checkpoint and/or augment the anti-cancer activity of DNA damaging treatments | CANBAS CO., LTD. (JP) | 2004-10-07 | — | — | US | claimed |
| WO-2003104181-A2 | COMPOUNDS THAT ABROGATE DNA-DAMAGE-INDUCED CELL CYCLE G2 CHECKPOINT AND/OR AUGMENT THE ANTI-CANCER ACTIVITY OF DNA-DAMAGING TREATMENTS | CANBAS CO. LTD. (JP) | 2003-12-18 | — | — | WO | claimed |
| US-8263268-B2 | Ester compound, and non-aqueous electrolyte solution and lithium secondary battery each using the ester compound | UBE INDUSTRIES, LTD. (JP) | 2012-09-11 | — | — | US | disclosed |
| EP-2108640-B1 | ESTER COMPOUND, AND NON-AQUEOUS ELECTROLYTE SOLUTION AND LITHIUM SECONDARY BATTERY EACH USING THE ESTER COMPOUND | UBE INDUSTRIES (JP) | 2012-07-25 | — | — | EP | disclosed |
| EP-1511713-B8 | COMPOUNDS THAT ABROGATE DNA-DAMAGE-INDUCED CELL CYCLE G2 CHECKPOINT AND/OR AUGMENT THE ANTI-CANCER ACTIVITY OF DNA-DAMAGING TREATMENTS | CANBAS CO LTD (JP) | 2012-02-08 | — | — | EP | disclosed |
| EP-1511713-A2 | COMPOUNDS THAT ABROGATE DNA-DAMAGE-INDUCED CELL CYCLE G2 CHECKPOINT AND/OR AUGMENT THE ANTI-CANCER ACTIVITY OF DNA-DAMAGING TREATMENTS | Canbas Co. Ltd. (JP) | 2005-03-09 | — | — | EP | disclosed |
| WO-2005014856-A1 | SENSITIVITY TEST TO PREDICT EFFICACY OF ANTI-CANCER THERAPIES | CANBAS CO., LTD. (JP) | 2005-02-17 | — | — | WO | disclosed |
| US-20040198727-A1 | Compounds that abrogate DNA-damage-induced cell cycle G2 checkpoint and/or augment the anti-cancer activity of DNA damaging treatments | CANBAS CO., LTD. (JP) | 2004-10-07 | — | — | US | disclosed |
| WO-2003104181-A2 | COMPOUNDS THAT ABROGATE DNA-DAMAGE-INDUCED CELL CYCLE G2 CHECKPOINT AND/OR AUGMENT THE ANTI-CANCER ACTIVITY OF DNA-DAMAGING TREATMENTS | CANBAS CO. LTD. (JP) | 2003-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293137-A1 | COMPOUNDS THAT ABROGATE DNA DAMAGE INDUCED CELL CYCLE G2 CHECKPOINT AND/OR AUGMENT ANTI-CANCER ACTIVITY OF DNA-DAMAGING TREATMENTS | CDC25C, CHEK1, CDC25A | PRSS1 4017/4885ACR 2467/4885CYP1A2 4303/4885 |
| US-20040198727-A1 | Compounds that abrogate DNA-damage-induced cell cycle G2 checkpoint and/or augment the anti-cancer activity of DNA damaging treatments | CDC25C, CHEK1, DDB1 | PRSS1 4149/4885ACR 2581/4885CYP1A2 4356/4885 |
| US-20080227827-A1 | COMPOUNDS THAT ABROGATE DNA DAMAGE INDUCED CELL CYCLE G2 CHECKPOINT AND/OR AUGMENT ANTI-CANCER ACTIVITY OF DNA-DAMAGING TREATMENTS | CDC25C, CHEK1, CDC25A | PRSS1 4017/4885ACR 2467/4885CYP1A2 4303/4885 |
| US-20060122269-A1 | Compounds that abrogate DNA damage induced cell cycle G2 checkpoint and/or augment anti-cancer activity of DNA-damaging treatments | CDC25C, CHEK1, CDC25A | PRSS1 4017/4885ACR 2467/4885CYP1A2 4303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.